What it is
Pharmacogenomics aims to improve outcomes by tailoring prescribing to a person's genes, but a lack of diversity in pharmacogenomics studies has held back its clinical use across populations. The authors used whole-genome sequences and electronic health records from nearly 100,000 participants in the US All of Us Research Program to estimate the frequencies of variants in 16 pharmacogenes (among them CYP2D6, CYP2C19, DPYD and SLCO1B1), the phenotypes those variants predict, and participants' exposure to affected medications. 100% of participants carried at least one pharmacogenomic variant, and 99.5% had a predicted phenotype with prescribing recommendations. The study also reports thousands of previously unrecognized pharmacogene variants, and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.
Why it matters
24.4% of participants had an actionable phenotype and had already been exposed to an affected medication with pharmacogenomic prescribing guidance. The authors call that clinical impact high, and it makes gene-guided prescribing a question for about one participant in four here, not a rare case. And because earlier pharmacogenomic studies lacked diversity, the new variants and the frequencies that differ from known ones, add data for populations those studies under-represented, especially the Americas and African ancestry groups.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underPharmacogenetics and Drug Metabolism, Genetic Associations and Epidemiology, Genomics and Rare Diseases